Two Sigma Securities, LLC Alzamend Neuro, Inc. Transaction History

Two Sigma Securities, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.19 - $0.52 $1,048 - $2,868	5,516 Added 24.36%	28,156 $6,000
Q2 2023 Aug 14, 2023	BUY	$0.49 - $0.77 $2,371 - $3,726	4,840 Added 27.19%	22,640 $11,000
Q1 2023 May 15, 2023	SELL	$0.37 - $0.71 $6,387 - $12,257	-17,264 Reduced 49.24%	17,800 $7,000
Q4 2022 Feb 14, 2023	BUY	$0.53 - $222.0 $18,583 - $7.78 Million	35,064 New	35,064 $19,000
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.2 $15,006 - $21,960	-18,300 Reduced 54.21%	15,458 $13,000
Q1 2022 May 16, 2022	BUY	$0.91 - $2.23 $2,880 - $7,057	3,165 Added 10.35%	33,758 $42,000
Q4 2021 Feb 14, 2022	BUY	$1.9 - $3.08 $58,126 - $94,226	30,593 New	30,593 $58,000
Q3 2021 Nov 15, 2021	SELL	$2.28 - $7.68 $36,521 - $123,018	-16,018 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.12 - $13.5 $130,066 - $216,243	16,018 New	16,018 $140,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.